Emgality works by blocking a protein called CGRP (calcitonin gene-related peptide) that plays a central role in triggering migraines. It’s a lab-engineered antibody designed to latch onto CGRP molecules in your bloodstream before they can activate pain pathways, and it starts working as early as the first day after injection.
The Role of CGRP in Migraines
CGRP is a small signaling protein found throughout your nervous system, especially in the nerves surrounding your brain. During a migraine, CGRP levels spike. The protein dilates blood vessels around the brain, triggers inflammation, and amplifies pain signals. In people with frequent migraines, this system is essentially overactive, releasing CGRP too easily or in too-large amounts.
Emgality (galcanezumab) is a humanized monoclonal antibody, which means it’s a large, precisely shaped protein engineered to grab onto one specific target. In this case, Emgality binds directly to the CGRP molecule itself, physically blocking it from attaching to its receptor. Think of it like putting a cap on a key so it can no longer fit into its lock. With CGRP unable to activate its receptor, the cascade of blood vessel dilation, inflammation, and pain signaling that produces a migraine is interrupted before it starts.
This is a preventive approach, not a rescue treatment. Emgality doesn’t stop a migraine once it’s underway. Instead, by keeping CGRP levels effectively neutralized over weeks, it reduces how often migraines occur in the first place.
How Quickly It Starts Working
One of Emgality’s more notable features is its speed. An analysis of the EVOLVE clinical trials found that patients were significantly less likely to experience a migraine starting on the very first full day after their initial injection. By the end of the first week, over half of patients on Emgality had already achieved at least a 50% reduction in migraine days, compared to roughly a third on placebo.
This rapid onset is partly why Emgality uses a loading dose. Your first treatment is 240 mg (two injections of 120 mg given back to back), which floods your system with enough antibody to start binding CGRP immediately. After that, you switch to a single 120 mg injection once a month to maintain the effect.
How Much It Reduces Migraines
In the EVOLVE-1 trial, which studied people with episodic migraine (4 to 14 migraine days per month), patients on Emgality experienced about 4.7 fewer migraine days per month, compared to 2.8 fewer days in the placebo group. That difference of roughly 2 additional migraine-free days per month may sound modest on paper, but for someone dealing with 8 or 10 migraine days a month, that reduction compounds into meaningful quality-of-life improvement over time.
Both the 120 mg and 240 mg doses performed nearly identically in trials, which is why the lower monthly maintenance dose became the standard.
Emgality for Cluster Headaches
Emgality is also the first and only CGRP-targeting treatment approved for episodic cluster headaches, which are a distinct and far more intense condition than migraines. For cluster headaches, the dosing is different: 300 mg once a month, injected as three separate 100 mg doses.
In a clinical trial published in The New England Journal of Medicine, patients on Emgality reduced their weekly cluster headache attacks by an average of 8.7 over the first three weeks, compared to 5.2 in the placebo group. That’s 3.5 fewer attacks per week. By week three, 71% of patients on Emgality had cut their attack frequency by at least half, compared to 53% on placebo.
How Long It Stays in Your Body
Emgality has an elimination half-life of about 27 days, meaning it takes roughly a month for half of the drug to clear your system. This long half-life is what makes once-monthly dosing possible. It also means that if you experience side effects, they won’t disappear overnight. After your last injection, it takes several months for the drug to fully leave your body.
The flip side is that if you miss a dose by a few days, you still have significant protection. The antibody doesn’t suddenly stop working the moment you pass the 30-day mark.
What the Injection Is Like
Emgality comes as a pre-filled pen or syringe designed for self-injection at home. You inject it under the skin of your stomach, thigh, or the back of your upper arm (though the arm typically requires someone else to help). The injection itself takes about 10 seconds.
Injection site reactions are the most commonly reported side effect. This typically means redness, itching, or mild pain at the spot where the needle went in. These reactions are generally mild and resolve on their own within a few days.
The medication needs to be stored in the refrigerator, but you can leave it out at room temperature (up to 86°F) for up to 7 days if needed, for instance while traveling. Once it’s been out of the fridge, don’t put it back. If it’s been at room temperature longer than 7 days, discard it.
How Emgality Differs From Acute Treatments
Traditional migraine medications like triptans work by constricting blood vessels and dampening pain signals after a migraine has already started. They’re effective for individual attacks but do nothing to reduce how often migraines happen. Overusing them can actually cause more frequent headaches over time.
Emgality takes the opposite approach. By continuously neutralizing CGRP between injections, it lowers the baseline excitability of your migraine circuitry. You may still get occasional migraines and still need acute medication for those, but the goal is fewer attacks overall. Many patients use Emgality as a preventive alongside a separate medication they take only when a migraine breaks through.
Other preventive options, like certain blood pressure medications and antidepressants, also reduce migraine frequency but weren’t designed for that purpose and come with broader systemic effects. Emgality targets only the CGRP pathway, which is why its side effect profile is relatively narrow compared to older preventive therapies.